Replies to post #12876 on Sorrento Therapeutics Inc (SRNE)

[1776club]

Anti-CD47s are a must have for Pfizer as they shell out $18.50 per share, in cash, representing an aggregate purchase price of approximately $2.22 billion to buy TRILLIUM for its two lead molecules which are in P1/2, TTI-622 and TTI-621 which enhances Pfizer’s Oncology portfolio with addition of next-generation, investigational immuno-therapeutics for hematological malignancies
Sorrento has got one of those that is in P1.
STI -6643 Sorrento Therapeutics Anti-CD47 antibody

https://ichgcp.net/clinical-trials-registry/NCT04900519

Don't get too excited these types of pharmaceuticals take many years to go through trials.